Manuela Funke-Chambour

List of Publications by Year
in descending order

35	968	623188 14	476904 29
papers	citations	h-index	g-index

42	42	42	1657
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	MRI Shows Lung Perfusion Changes after Vaping and Smoking. Radiology, 2022, 304, 195-204.	3.6	9
2	The Octopus Signâ€"A New HRCT Sign in Pulmonary Langerhans Cell Histiocytosis. Diagnostics, 2022, 12, 937.	1.3	2
3	Frailty assessment for COVID-19 follow-up: a prospective cohort study. BMJ Open Respiratory Research, 2022, 9, e001227.	1.2	12
4	Fatigue in Post-COVID-19 Syndrome: Clinical Phenomenology, Comorbidities and Association With Initial Course of COVID-19. Journal of Central Nervous System Disease, 2022, 14, 117957352211027.	0.7	6
5	Influence of ventilation inhomogeneity on diffusing capacity of carbon monoxide in smokers without COPD. ERJ Open Research, 2021, 7, 00706-2020.	1.1	1
6	Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. European Respiratory Journal, 2021, 57, 2003690.	3.1	291
7	Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts. BMJ Open Respiratory Research, 2021, 8, e000827.	1.2	13
8	Performance of a diagnostic algorithm for fibrotic hypersensitivity pneumonitis. A caseâ€"control study. Respiratory Research, 2021, 22, 120.	1.4	4
9	Human-Based Advanced in vitro Approaches to Investigate Lung Fibrosis and Pulmonary Effects of COVID-19. Frontiers in Medicine, 2021, 8, 644678.	1.2	31
10	Azithromycin for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis: A Randomized Controlled Crossover Trial. Annals of the American Thoracic Society, 2021, 18, 2018-2026.	1.5	19
11	Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease. Chest, 2021, 160, 994-1005.	0.4	20
12	Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World. Frontiers in Medicine, 2021, 8, 699644.	1.2	8
13	Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey. European Respiratory Journal, 2021, 57, 2004219.	3.1	2
14	Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID. Respiration, 2021, 100, 826-841.	1.2	41
15	Imaging in the aftermath of COVID-19: what to expect. European Radiology, 2021, 31, 4390-4392.	2.3	17
16	Evaluation of a Novel Ear Pulse Oximeter: Towards Automated Oxygen Titration in Eyeglass Frames. Sensors, 2020, 20, 3301.	2.1	2
17	Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. European Respiratory Journal, 2020, 55, 1901760.	3.1	61
18	Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls. Respiratory Research, 2020, 21, 25.	1.4	26

#	Article	IF	Citations
19	Registries for Idiopathic Pulmonary Fibrosis: When Is It Time to Go Global?. Annals of the American Thoracic Society, 2020, 17, 1378-1379.	1.5	2
20	New radiological diagnostic criteria: impact on idiopathic pulmonary fibrosis diagnosis. European Respiratory Journal, 2019, 54, 1900905.	3.1	4
21	Antifibrotics: Shrinking the Box of Therapeutic Uncertainty. Respiration, 2019, 97, 202-204.	1.2	0
22	Multiple breath washout: A new and promising lung function test for patients with idiopathic pulmonary fibrosis. Respirology, 2018, 23, 764-770.	1.3	14
23	Medium throughput breathing human primary cell alveolus-on-chip model. Scientific Reports, 2018, 8, 14359.	1.6	132
24	Human microvasculature-on-aÂchip: anti-neovasculogenic effect of nintedanib in vitro. Angiogenesis, 2018, 21, 861-871.	3.7	36
25	Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis â€“ a potential biomarker role for LysoPC. Respiratory Research, 2018, 19, 7.	1.4	58
26	Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre. Swiss Medical Weekly, 2018, 148, w14577.	0.8	8
27	Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment. Respiration, 2017, 93, 363-378.	1.2	26
28	Surfactant replacement therapy reduces acute lung injury and collapse induration-related lung remodeling in the bleomycin model. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L313-L327.	1.3	39
29	Perioperative Lung Function Monitoring for Anatomic Lung Resections. Annals of Thoracic Surgery, 2017, 104, 1725-1732.	0.7	5
30	Novel insights in cough and breathing patterns of patients with idiopathic pulmonary fibrosis performing repeated 24-hour-respiratory polygraphies. Respiratory Research, 2017, 18, 190.	1.4	13
31	P054 <break /> Exhaled breath condensate- a potential biomarker tool for patients with idiopathic pulmonary fibrosis?. QJM - Monthly Journal of the Association of Physicians, 2016, , .	0.2	0
32	Lysophosphatidic Acid Signaling through the Lysophosphatidic Acid-1 Receptor Is Required for Alveolarization. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 105-116.	1.4	24
33	Multidisciplinary discussion for diagnosis of interstitial lung disease in real life. Swiss Medical Weekly, 2016, 146, w14318.	0.8	5
34	Pulmonary hypertension associated with chronic lung diseases. Swiss Medical Weekly, 2016, 146, w14363.	0.8	4
35	Idiopathic pulmonary fibrosis: the turning point is now!. Swiss Medical Weekly, 2015, 145, w14139.	0.8	18